Stem Cell Advisor

What are Natural Killer Cells? Natural killer (NK) cells, a specific type of white blood cell, are an important component of your innate immune system. Your immune system consists of two different branches — cell-mediated immunity (innate) and humoral immunity (adaptive). When you contract a viral disease, the pathogen enters your body and infects your cells. NK Cell Therapy Market Size The global natural killer cells therapeutics market reached a value of US$ 2.1 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 5.1 Billion by 2027 ( R ). Analysis by Data Bridge Market Research reported that the Natural Killer (NK) Cell Therapeutics Market will grow at a CAGR (compound annual growth rate) of 40.9% during the forecast by 2029. NK cell for cancer immunotherapy Benefits and Side Effects of Transfusing NK Cells In terms of benefits, NK cells are the hardest to produce in the body, so transfusing a large amount automatically strengthens the patient’s immune sy...

One of the most promising approaches in cellular therapies is immunotherapies using engineered T cells or natural killer (NK) cells expressing chimeric antigen receptors (CARs). Will CAR-NK cell therapies overshadow traditional CAR-T options for the treatment of some cancers? As of June 2024,  more than 50 studies  have been launched to investigate the potential of CAR-NK cell therapy. While CAR T-cell therapy is more well-known and studied, there are challenges to the manufacturing of CAR T that does not exist with CAR-NK. This may prove to be a game-changer for blood cancer patients who do not have the time to wait for a CAR T-cell donor or for their own cells to be engineered for treatment. Researchers have tried to modify natural killer (NK) cells with chimeric antigen receptors (CAR) to increase potential to bind and destroy cancer cells, known as NK cell therapy. Here we describe the differences between CAR T ce...

One of the most promising approaches in cellular therapies is immunotherapies using engineered T cells or natural killer (NK) cells expressing chimeric antigen receptors (CARs). Will CAR-NK cell therapies overshadow traditional CAR-T options for the treatment of some cancers? As of April 2023,  more than 1,100 studies  have been launched to investigate the potential of CAR-T cell therapy under the U.S. Clinical Trial Registry. Whereas for CAR-NK cell therapy,  more than 50 studies  have been launched. While CAR T-cell therapy is more well-known and studied, there are challenges to the manufacturing of CAR T that does not exist with CAR-NK. This may prove to be a game-changer for blood cancer patients who do not have the time to wait for a CAR T-cell donor or for their own cells to be engineered for treatment. Researchers have tried to modify natural killer (NK) cells with chimeric antigen receptors (CAR) to increase potential to bind and destroy cancer cells, known a...